ZIOPHARM to Present at the 36th Annual J.P. Morgan Healthcare Conference

BOSTON, Dec. 21, 2017 -- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the 36^th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 11, 2018 at 10 a.m. PST. The presentation will include a detailed update on the Company’s clinical development programs and corporate development efforts.

To access a live audio webcast of the presentation, please visit the Investor Relations section at www.ziopharm.com. The webcast will be archived for 90 days.

About ZIOPHARM Oncology, Inc.

ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology company employing innovative gene expression, control and cell technologies to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. The Company's immuno-oncology programs, in collaboration with Intrexon Corporation (NYSE:XON) and the MD Anderson Cancer Center, include chimeric antigen receptor T cell (CAR-T) and other adoptive cell-based approaches that use non-viral gene transfer methods for broad scalability. The Company is advancing programs in multiple stages of development together with Intrexon Corporation's RheoSwitch Therapeutic System^® (RTS^®) technology, a switch to turn on and off, and precisely modulate, gene expression such as IL-12 in order to improve therapeutic index. The Company's pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies.

Contact:
David Connolly
ZIOPHARM Oncology
617-502-1881
[email protected]

David Pitts
Argot Partners
212-600-1902
[email protected]